Fig. 1 · Structure

Documents & Downloads

HS-173

Cat. No. A13021 CAS 1276110-06-5

PI3K Inhibitor

HS-173, a novel phosphatidylinositol 3-kinase (PI3K) inhibitor, has anti-tumor activity through promoting apoptosis and inhibiting angiogenesis.

In Stock

Publications for HS-173

2 publications citing this product

  1. Mostafa Khater, .et al. , J Biol Chem, 2021, Jan-Jun, 296:100805 PMID: 34022220
  2. Mostafa Khater, .et al. , J Biol Chem, 2021, Jan 22;296:100325 PMID: 33493514

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

HS-173 reduced Akt and P70S6K phosphorylation in HSC-T6 and LX-2 cells. These results support cellular PI3K-pathway inhibition; they do not determine direct enzyme potency or isoform selectivity. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
PI3Kα 0.8 nM

Cellular Effect

Cell Line Activity Value Description Reference
A549 IC50 0.26 μM Antiproliferative activity against human A549 cells after 72 hrs by SRB assay [PMID: 28800461]
HCT-116 IC50 0.25 μM Cytotoxicity against human HCT116 cells harboring PIK3CA mutant assessed as reduction in cell viability measured after 72 hrs by CCK8 assay [PMID: 32069401]
HCT-116 IC50 0.54 μM Antiproliferative activity against human HCT116 cells after 72 hrs by SRB assay [PMID: 28800461]
MCF7 IC50 7.8 μM Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay [PMID: 21388141]
MDA-MB-231 IC50 0.76 μM Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by SRB assay [PMID: 28800461]
SK-BR-3 IC50 1.5 μM Cytotoxicity against human SK-BR-3 cells after 48 hrs by MTT assay [PMID: 21388141]
SK-HEP1 IC50 1.09 μM Antiproliferative activity against human SKHEP1 cells after 72 hrs by SRB assay [PMID: 28800461]
SNU-638 IC50 0.68 μM Antiproliferative activity against human SNU638 cells after 72 hrs by SRB assay [PMID: 28800461]
T47D IC50 0.6 μM Cytotoxicity against human T47D cells after 48 hrs by MTT assay [PMID: 21388141]

9 records · Scroll to view more

HS-173 Research Summary

This section summarizes 4 in vitro studies and 1 in vivo study of HS-173 from 4 published references. In vitro models include HSC-T6 and LX-2 hepatic stellate cell lines; DU145, PC3 and HEK293 cells.

HS-173 In Vitro Studies

Activity depends on the signaling endpoint. At 0.1 μM with 6 h pretreatment, HS-173 did not inhibit SDF1α-induced ERK1/2 phosphorylation or significantly inhibit ARF1 activation in DU145, PC3 and HEK293 cells. [2,3]

In human stem cell-derived cardiomyocytes, HS-173 produced concentration-dependent apoptotic signaling across a 0.03–1 μM test range. Apoptosis at 0.03 μM was labeled nonsignificant. This provides a cellular liability signal without establishing clinical cardiac risk. [4]

Akt/P70S6K phosphorylation in hepatic stellate cells

Cell-based study · HSC-T6 and LX-2 hepatic stellate cell lines [1]

HS-173 lowered Akt and P70S6K phosphorylation in both lines. These cellular readouts support pathway inhibition, without establishing direct PI3Kα enzyme potency or isoform selectivity.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
p-Akt/Akt and p-P70S6K/P70S6Kqualitative change Reduced with HS-173; mean ± S.D., three independent experiments[1]

Literature-Reported Treatment Conditions

Treatment concentration
0.1, 1 and 5 μM (24 h); 1 and 5 μM in the 6 h comparison with LY294002
Exposure duration
24 h (Figure 5A); 6 h (Figure 5B)
Method
Cell treatment followed by immunoblotting
Vehicle
DMSO stock; final vehicle concentration for Figure 5 is not specified
Reported limits
Figure 5-specific vehicle concentration is not stated.
Methods and source locations

Compound reported in the paper: HS-173

Reported experimental HS-173 material; no equivalence to an Adooq lot, salt conversion, or clinical efficacy is inferred.

Figure 5A–B and caption; Results: HS-173 suppresses PI3K/Akt signaling; Methods: Preparation of HS-173, Western blotting

p-Akt/Akt and p-P70S6K/P70S6K: Western blotting with total Akt, total P70S6K and β-actin controls — Figure 5A–B and caption; Results: HS-173 suppresses PI3K/Akt signaling; Methods: Preparation of HS-173, Western blotting

HS-173 comparison in SDF1α-induced ERK signaling

Cell-based study · DU145, PC3 and HEK293 cells [2]

HS-173 did not visibly inhibit SDF1α-induced ERK1/2 phosphorylation under the tested condition; PI3Kγ/δ inhibitor comparators reduced the response.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
SDF1α-induced ERK1/2 phosphorylationqualitative change No effect reported for HS-173; blots representative of at least three experiments[2]

Literature-Reported Treatment Conditions

Treatment concentration
0.1 μM
Exposure duration
6 h pretreatment; SDF1α challenge for 5 min
Method
Immunoblot assay
Co-treatment
SDF1α 200 ng/mL challenge; other inhibitors were separate comparator conditions
Reported limits
HS-173 vehicle and catalog/lot identifiers are not specified in the reviewed methods.
Methods and source locations

Compound reported in the paper: HS-173

Reported experimental HS-173 material; no equivalence to an Adooq lot, salt conversion, or clinical efficacy is inferred.

Figure 4A and caption; Results: pharmacological inhibition of Gβγ downstream effectors; Experimental procedures: Materials, ERK1/2 activation

SDF1α-induced ERK1/2 phosphorylation: Phospho-ERK1/2 immunoblot with total ERK1/2 controls — Figure 4A and caption; Results: pharmacological inhibition of Gβγ downstream effectors; Experimental procedures: Materials, ERK1/2 activation

HS-173 comparison in SDF1α-induced ARF1 activation

Cell-based study · DU145, PC3 and HEK293 cells [3]

HS-173 did not significantly inhibit SDF1α-induced ARF1 activation, whereas PI3Kγ-directed comparator inhibition reduced activation.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Active ARF1 relative to total ARF1qualitative change No significant inhibition reported for HS-173; quantitative data mean ± SD (n = 3)[3]

Literature-Reported Treatment Conditions

Treatment concentration
0.1 μM
Exposure duration
6 h pretreatment; SDF1α challenge for 5 min
Method
Cellular ARF1 activation assay
Co-treatment
SDF1α 200 ng/mL challenge; inhibitor comparators were separate conditions
Reported limits
HS-173 vehicle and catalog/lot identifiers are not specified in the reviewed methods.
Methods and source locations

Compound reported in the paper: HS-173

Reported experimental HS-173 material; no equivalence to an Adooq lot, salt conversion, or clinical efficacy is inferred.

Figure 5A–B and caption; Results: PI3Kγ mediates ARF1 activation; Experimental procedures: Materials, GST fusion protein pulldown assays

Active ARF1 relative to total ARF1: GST–VHS–GAT pulldown followed by ARF1 immunoblotting — Figure 5A–B and caption; Results: PI3Kγ mediates ARF1 activation; Experimental procedures: Materials, GST fusion protein pulldown assays

Apoptotic signaling in human stem cell-derived cardiomyocytes

Cell-based study · Cor.4U human stem cell-derived cardiomyocytes [4]

HS-173 increased caspase-3/7 activity in this cellular model. The lowest tested concentration was labeled nonsignificant. This does not establish clinical cardiac risk.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Caspase-3/7 apoptosis signalqualitative change Concentration-dependent increase; 0.03 μM labeled ns (caption defines ns as p > 0.1); plotted mean ± SEM, 3–5 repeats per time point[4]

Literature-Reported Treatment Conditions

Treatment concentration
0.03, 0.1, 0.3 and 1 μM
Exposure duration
Apoptosis monitored over 24 h
Method
Live-cell caspase-3/7 imaging
Vehicle
0.1% v/v DMSO control
Reported limits
The linked raw-data workbook request returned HTML rather than an XLSX file. No clinical exposure threshold is established for HS-173.
Methods and source locations

Compound reported in the paper: HS-173

Reported experimental HS-173 material; no equivalence to an Adooq lot, salt conversion, or clinical efficacy is inferred.

Figure 2B and caption; Tables 1 and 3; Results: Apoptosis, Beating Rate and Base Impedance, ATP; Materials and Methods

Caspase-3/7 apoptosis signal: Live-cell caspase-3/7 imaging during 24 h — Figure 2B (HS-173 graph) and caption; Results: Apoptosis

HS-173 In Vivo Studies

In a mouse liver-injury model, oral HS-173 at 10 or 20 mg/kg during concurrent CCl4 exposure was associated with less collagen staining and lower serum AST/ALT than the CCl4 group. This four-week experiment addresses concurrent treatment rather than reversal of established fibrosis; oral vehicle matching of disease controls was not explicitly described. [1]

Concurrent HS-173 treatment in mouse liver fibrosis

Animal study · Male BALB/c mice with CCl4-associated liver fibrosis; four groups, n=8 each [1]

The treated groups showed less collagen staining and lower liver-injury markers than the CCl4 group during concurrent exposure. Disease-control oral vehicle matching was not explicitly described.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Collagen/fibrogenic staining and phospho-Akt/P70S6K stainingqualitative change Lower staining in HS-173 groups than the CCl4 group[1]
Serum AST and ALTqualitative change Lower in both HS-173 groups; mean ± S.D. (n = 8). Caption: *P < 0.05 and **P < 0.01 versus CCl4-treated group[1]

Conditions shared by the study groups

Route
Oral administration
Frequency
6 days per week
Treatment course
One month, concurrent with CCl4 exposure; assessment after 4 weeks
Vehicle
DMSO:PEG400:distilled water = 1:5:4
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
HS-173 10 mg/kgCCl4-treated group; separate corn-oil control group. Matching oral vehicle in the CCl4-only group is not explicitly described.Less collagen staining and lower serum AST/ALT than the CCl4 group; reduced fibrogenic and phospho-Akt/P70S6K staining.[1]
HS-173 20 mg/kgCCl4-treated group; separate corn-oil control group. Matching oral vehicle in the CCl4-only group is not explicitly described.Less collagen staining and lower serum AST/ALT than the CCl4 group; reduced fibrogenic and phospho-Akt/P70S6K staining.[1]
HS-173 10 mg/kg
Model: Male BALB/c mice, 6 weeks old; CCl4-induced liver injury/fibrosis; n=8 per group
Reported limits: Oral-vehicle matching of disease controls is not explicitly described. Histological assessment was blinded; blinding of other endpoints is unspecified.
HS-173 20 mg/kg
Model: Male BALB/c mice, 6 weeks old; CCl4-induced liver injury/fibrosis; n=8 per group
Reported limits: Oral-vehicle matching of disease controls is not explicitly described. Histological assessment was blinded; blinding of other endpoints is unspecified.
Methods and source locations

Compound reported in the paper: HS-173

Reported experimental HS-173 material; no equivalence to an Adooq lot, salt conversion, or clinical efficacy is inferred.

Figures 6–7 and captions; Results: mouse liver fibrosis and ECM/PI3K signaling; Methods: Animals, liver histopathology, serum parameters

Collagen/fibrogenic staining and phospho-Akt/P70S6K staining: Masson trichrome and immunostaining; descriptive image assessment — Figure 6A; Figure 7A–C and captions

Serum AST and ALT: Serum liver-function assays — Figure 6B and caption; Methods: Assessment of biochemical parameters

HS-173 10 mg/kg · Figures 6–7 and captions; Results: mouse liver fibrosis and ECM/PI3K signaling; Methods: Animals, liver histopathology, serum parameters

HS-173 20 mg/kg · Figures 6–7 and captions; Results: mouse liver fibrosis and ECM/PI3K signaling; Methods: Animals, liver histopathology, serum parameters

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 1276110-06-5
Applications PI3K Inhibitor
Formula C21H18N4O4S
Molecular Weight 422.1
SMILES
CCOC(=O)C1=CN=C2N1C=C(C=C2)C3=CC(=CN=C3)NS(=O)(=O)C4=CC=CC=C4

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO Warmed: 81 mg/mL (191.73 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
7 mg/mL
Vehicle
5% DMSO+30% PEG 300+5% Tween 80+ddH2O

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

HS-173 Research References

  1. [1] Son Mi Kwon, Ryu Ye-Lim, Jung Kyung Hee, et al. HS-173, a Novel PI3K Inhibitor, Attenuates the Activation of Hepatic Stellate Cells in Liver Fibrosis Scientific Reports (2013). PMID: 24326778 DOI: 10.1038/srep03470 Source material
  2. [2] Khater Mostafa, Wei Zhe, Xu Xin, et al. G protein βγ translocation to the Golgi apparatus activates MAPK via p110γ-p101 heterodimers The Journal of Biological Chemistry (2021). PMID: 33493514 DOI: 10.1016/j.jbc.2021.100325 Source material
  3. [3] Khater Mostafa, Bryant Christian N, Wu Guangyu. Gβγ translocation to the Golgi apparatus activates ARF1 to spatiotemporally regulate G protein–coupled receptor signaling to MAPK The Journal of Biological Chemistry (2021). PMID: 34022220 DOI: 10.1016/j.jbc.2021.100805 Source material
  4. [4] Ziegler Ricarda, Häusermann Fabian, Kirchner Stephan, et al. Cardiac Safety of Kinase Inhibitors – Improving Understanding and Prediction of Liabilities in Drug Discovery Using Human Stem Cell-Derived Models Frontiers in Cardiovascular Medicine (2021). PMID: 34222360 DOI: 10.3389/fcvm.2021.639824 Source material

Publications

2 publications citing this product

  1. Mostafa Khater, .et al. , J Biol Chem, 2021, Jan-Jun, 296:100805 PMID: 34022220
  2. Mostafa Khater, .et al. , J Biol Chem, 2021, Jan 22;296:100325 PMID: 33493514

Added to your cart

View Cart Checkout
Loading...